Logo for Corcept Therapeutics Incorporated

Corcept Therapeutics Investor Relations Material

Latest events

Logo for Corcept Therapeutics Incorporated

Q4 2023

Corcept Therapeutics
Logo for Corcept Therapeutics

Q4 2023

15 Feb, 2024
Logo for Corcept Therapeutics

Q3 2023

1 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders. The company offers Korlym tablets for use as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance, and who have failed surgery or are not candidates for surgery; Korlym tablets reducing cortisol is the key to improving cardiovascular abnormalities in people with mild Cushing's syndrome. It sells its products through specialty pharmacies and distributors. The company was founded in 1988 and is based in Menlo Park.